2024乳房醫學線上研討會，今年度共3場會議，將於6/28, 8/02, 09/06，在乳e學院線上進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!

誠摯歡迎各位學員於6月27日(四)18:40登入乳e學院並”加入我的課程+”，收看聆聽講師們分享ESMO Breast Cancer 治療最新趨勢!

Post- 2024 EBCC Highlight 即將於4/29(一)18:50-21:20線上直播，歡迎各位會員踴躍加入我的課程，聆聽歐洲最新乳癌治療趨勢!

2024與大師有約系列複習課程! 當紅炸子雞 Prof. Paolo Tarantino 以及國內乳癌治療專家劉峻宇醫師共同擔任講者，由台大盧彥伸教授及台北榮總曾令民教授共同主持，ㄧ起深度討論如何治療HER2-low 的病人。

Recent approved premenopausal patient reimbursement in Jan. 2024. Through this program we would like to review the current clinical reference and real world experience of treating  premenopausal patient to provide a clear picture based on reimbursement criteria, clinical reference and treatment experience.

The recent approval of the fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) for subcutaneous injection provides a more convenient treatment option for HER2-positive breast cancer. This ready-to-use formulation combines two essential HER2-targeted antibodies in one single dose, delivering a proven efficacious regimen without compromising safety or outcomes compared to the standard intravenous preparations. By reducing administration time to just minutes, PH FDC SC maximizes patient comfort and flexibility. This innovative pharmaceutical solution epitomizes the next step forward in improving care delivery for the subset of breast cancer patients who can benefit from dual HER2 blockade. Ultimately, optimizing convenience through developments like PH FDC SC may help to reduce barriers to adherence.